A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

CONCLUSION: Xeligekimab showed high efficacy and is well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.PMID:38366639 | DOI:10.1093/bjd/ljae062

https://pubmed.ncbi.nlm.nih.gov/38366639/?utm_source=no_user_agent&utm_medium=rs...

Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: Lin Cai Congjun Jiang Guoqiang Zhang Hong Fang Jinyan Wang Yumei Li Hui Xu Rong Xiao Yangfeng Ding Kun Huang Chunlei Zhang Litao Zhang Bin Chen Xinsuo Duan Weili Pan Guangming Han Rongyi Chen Lunfei Liu Shoumin Zhang Juan Tao Xiaowen Pang Jianbin Yu Huipi Source Type: research